Free Trial
NASDAQ:STOK

Stoke Therapeutics Q1 2024 Earnings Report

Stoke Therapeutics logo
$9.61 -0.12 (-1.23%)
Closing price 04:00 PM Eastern
Extended Trading
$9.54 -0.06 (-0.68%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stoke Therapeutics EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.60
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Stoke Therapeutics Revenue Results

Actual Revenue
$4.22 million
Expected Revenue
$3.33 million
Beat/Miss
Beat by +$890.00 thousand
YoY Revenue Growth
N/A

Stoke Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Monday, May 6, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Stoke Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 7:15 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Stoke Therapeutics Earnings Headlines

Needham Keeps Their Buy Rating on Stoke Therapeutics (STOK)
How I make 💰 trading from 135 countries
I’ve traveled to 135 countries… In a new time zone almost every week… (Often 8… 12… 16 hours AHEAD of the United States) And yet I’ve made $7.9 million career profits… trading in the US markets?
See More Stoke Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Stoke Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stoke Therapeutics and other key companies, straight to your email.

About Stoke Therapeutics

Stoke Therapeutics (NASDAQ:STOK), an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

View Stoke Therapeutics Profile

More Earnings Resources from MarketBeat